Apellis Pharmaceuticals, Inc. (APLS) Financial Statements (2026 and earlier)

Company Profile

Business Address 100 FIFTH AVENUE
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments466,233479,171370,036358,393411,290396,864
Cash and cash equivalent466,233479,171370,036358,393411,290396,864
Restricted cash and investments1,5271,4301,4301,4341,3221,373
Receivables366,221345,538214,131235,246264,926279,011
Inventory, net of allowances, customer advances and progress billings142,556122,819121,00082,46881,404121,058
Inventory142,556122,819121,00082,46881,404121,058
Prepaid expense9,51531,56029,17137,10418,36823,809
Other current assets  10,15819,84213,07311,64411,782
Other undisclosed current assets28,788     
Total current assets:1,014,840990,676755,610727,718788,954833,897
Noncurrent Assets
Inventory, Noncurrent34,95940,90948,12860,65275,71346,080
Operating lease, right-of-use asset18,19519,72014,63715,25116,08317,060
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization1,7081,9272,1172,5142,9523,379
Other noncurrent assets5,5555,4918981,1501,3491,450
Total noncurrent assets:60,41768,04765,78079,56796,09767,969
TOTAL ASSETS:1,075,2571,058,723821,390807,285885,051901,866
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities222,847178,924193,240171,433178,756182,565
Accounts payable56,79838,60254,24155,28738,57242,730
Accrued liabilities166,049140,322138,999116,146140,184139,835
Debt93,66293,581    
Other undisclosed current liabilities7,0877,0227,4196,9446,7538,695
Total current liabilities:323,596279,527200,659178,377185,509191,260
Noncurrent Liabilities
Long-term debt and lease obligation361,664361,091454,035453,422452,830452,245
Long-term debt, excluding current maturities361,664361,091454,035453,422452,830452,245
Liabilities, other than long-term debt19,85016,93710,39111,27018,17321,240
Other liabilities7,9033,2572,0782,0847,9729,829
Operating lease, liability11,94713,6808,3139,18610,20111,411
Total noncurrent liabilities:381,514378,028464,426464,692471,003473,485
Total liabilities:705,110657,555665,085643,069656,512664,745
Equity
Equity, attributable to parent370,147401,168156,305164,216228,539237,121
Common stock121212121212
Additional paid in capital3,385,2163,357,5833,328,6043,294,8493,267,2013,239,262
Accumulated other comprehensive loss(2,103)(2,400)(2,569)(3,054)(3,308)(3,140)
Accumulated deficit(3,012,978)(2,954,027)(3,169,742)(3,127,591)(3,035,366)(2,999,013)
Total equity:370,147401,168156,305164,216228,539237,121
TOTAL LIABILITIES AND EQUITY:1,075,2571,058,723821,390807,285885,051901,866

Income Statement (P&L) ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Revenues199,913458,578178,494166,797212,528196,830
Cost of revenue
(Cost of Product and Service Sold)
(900)  (23,400)(4,900) 
Gross profit:199,013458,578178,494143,397207,628196,830
Operating expenses(251,055)(235,395)(211,780)(250,125)(238,692)(244,110)
Other undisclosed operating income900  23,4004,900 
Operating income (loss):(51,142)223,183(33,286)(83,328)(26,164)(47,280)
Nonoperating income3,3514,4132,7532,4931,6312,959
Investment income, nonoperating3,5024,3762,6072,6583,3962,889
Other nonoperating income (expense)(151)37146(165)(1,765)70
Interest and debt expense(10,847)(11,279)(11,152)(11,049)(11,534)(12,532)
Income (loss) from continuing operations before income taxes:(58,638)216,317(41,685)(91,884)(36,067)(56,853)
Income tax expense(313)(602)(466)(341)(286)(592)
Net income (loss) available to common stockholders, basic:(58,951)215,715(42,151)(92,225)(36,353)(57,445)
Interest on convertible debt903903    
Net income (loss) available to common stockholders, diluted:(58,048)216,618(42,151)(92,225)(36,353)(57,445)

Comprehensive Income ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Net income (loss):(58,951)215,715(42,151)(92,225)(36,353)(57,445)
Comprehensive income (loss):(58,951)215,715(42,151)(92,225)(36,353)(57,445)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent297169485254(168)222
Comprehensive income (loss), net of tax, attributable to parent:(58,654)215,884(41,666)(91,971)(36,521)(57,223)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: